Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma

Digestive and Liver Disease

Volumn 47, Issue 12, 2015, Pages 1067-1075

  Matsushima, Hajime ^a   Kuroki, Tamotsu ^a   Kitasato, Amane ^a   Adachi, Tomohiko ^a   Tanaka, Takayuki ^a   Hirabaru, Masataka ^a   Hirayama, Takanori ^a   Kuroshima, Naoki ^a   Hidaka, Masaaki ^a   Soyama, Akihiko ^a   Takatsuki, Mitsuhisa ^a   Kinoshita, Naoe ^b   Sano, Kazunori ^a   Nishida, Noriyuki ^a   Eguchi, Susumu ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biliary intraepithelial neoplasia; Intrahepatic cholangiocarcinoma; Sox9

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR SOX9; UVOMORULIN; VIMENTIN; BIOLOGICAL MARKER; SOX9 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM; FEMALE; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER RESECTION; MALE; OVERALL SURVIVAL; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VERY ELDERLY; BILE DUCT TUMOR; CARCINOMA IN SITU; CELL CULTURE TECHNIQUE; INTRAHEPATIC BILE DUCT; JAPAN; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS; CARCINOMA IN SITU; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; SOX9 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84983120435     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.08.003     Document Type: Article

References (47)

1. Blechacz B., Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48:308-321.
2. Olnes M.J., Erlich R. A review and update on cholangiocarcinoma. Oncology 2004, 66:167-179.
3. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353-1357.
4. Sano T., Shimada K., Sakamoto Y., et al. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Annals of Surgery 2006, 244:240-247.
5. Kim Y.I., Park J.W., Kim B.H., et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiation Oncology 2013, 8:292.
6. Kitajima T., Tajima Y., Matsuzaki S., et al. Acceleration of spontaneous biliary carcinogenesis in hamsters by bilioenterostomy. Carcinogenesis 2003, 24:133-137.
7. Castello-Megias V.M., Ibarrola-de Andres C., Colina-Ruizdelgado F. Pathological aspects of so called "hilar cholangiocarcinoma". World Journal of Gastrointestinal Oncology 2013, 5:159-170.
8. Nakanuma Y., Sasaki M., Sato Y., et al. Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. World Journal of Hepatology 2009, 1:35-42.
9. Akiyama H. Control of chondrogenesis by the transcription factor Sox9. Modern Rheumatology 2008, 18:213-219.
10. Jiang T., Hou C.C., She Z.Y., et al. The SOX gene family: function and regulation in testis determination and male fertility maintenance. Molecular Biology Reports 2013, 40:2187-2194.
11. Akiyama H., Chaboissier M.C., Behringer R.R., et al. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:6502-6507.
12. Maeda Y., Dave V., Whitsett J.A. Transcriptional control of lung morphogenesis. Physiological Reviews 2007, 87:219-244.
13. Seymour P.A., Freude K.K., Tran M.N., et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:1865-1870.
14. Antoniou A., Raynaud P., Cordi S., et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 2009, 136:2325-2333.
15. Pompolo S., Harley V.R. Localisation of the SRY-related HMG box protein, SOX9, in rodent brain. Brain Research 2001, 906:143-148.
16. Buckler A.J., Pelletier J., Haber D.A., et al. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Molecular and Cellular Biology 1991, 11:1707-1712.
17. Chu D., Kakazu N., Gorrin-Rivas M.J., et al. Cloning and characterization of LUN, a novel ring finger protein that is highly expressed in lung and specifically binds to a palindromic sequence. Journal of Biological Chemistry 2001, 276:14004-14013.
18. Guo X., Xiong L., Sun T., et al. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagnostic Pathology 2012, 7:44.
19. Song S., Maru D.M., Ajani J.A., et al. Loss of TGF-β adaptorβ2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Research 2013, 73:2159-2169.
20. Seshikawa Kimura M., Mutoh H., Sugano K. SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humans. Journal of Gastroenterology 2011, 46:1292-1299.
21. Lu B., Fang Y., Xu J., et al. Analysis of SOX9 expression in colorectal cancer. American Journal of Clinical Pathology 2008, 130:897-904.
22. Zhou C.J., Guo J.Q., Zhu K.X., et al. Elevated expression of SOX9 is related with the progression of gastric carcinoma. Diagnostic Cytopathology 2011, 39:105-109.
23. Tanaka T., Kuroki T., Adachi T., et al. Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm. Pancreas 2013, 42:488-493.
24. Kuroki T., Tanaka T., Kitasato A., et al. Decreased expression of SOX9 in intraductal papillary mucinous neoplasms of the bile duct. Hepato-Gastroenterology 2013, 60:1573-1576.
25. Shroff S., Rashid A., Wang H., et al. SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. Human Pathology 2014, 45:456-463.
26. Sobin L.H., Gospodarowicz M., Wittekind C. TNM classification of malignant tumors (UICC) 2009, Wiley-Blackwell, New York. 7th ed.
27. Pinho A.C., Melo R.B., Oliveira M., et al. Adenoma-carcinoma sequence in intrahepatic cholangiocarcinoma. International Journal of Surgery Case Reports 2012, 3:131-133.
28. Fava G., Lorenzini I. Molecular pathogenesis of cholangiocarcinoma. International Journal of Hepatology 2012, 10.1155/2012/630543.
29. O'Dell M.R., Huang J.L., Whitney-Miller C.L., et al. Kras (G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Research 2012, 72:1557-1567.
30. Tannapfel A., Benicke M., Katalinic A., et al. Frequency of p16(INK4A) alternations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000, 47:721-727.
31. Hsu M., Sasaki M., Igarashi S., et al. KRAS and GNAS mutations and p53 overexpression in biliary intrahepatic neoplasia and intrahepatic cholangiocarcinomas. Cancer 2013, 119:1669-1674.
32. Pinho A.V., Rooman I., Real F.X. p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle 2011, 10:1312-1321.
33. Kopp J.L., von Figura G., Mayes E., et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:737-750.
34. Capaccione K.M., Hong X., Morgan K.M., et al. Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma. Oncotarget 2014, 5:3636-3650.
35. Furuyama K., Kawaguchi Y., Akiyama H., et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nature Genetics 2011, 1:34-43.
36. Sun M., Uozaki H., Hino R., et al. Sox9 expression and its methylation status in gastric cancer. Virchows Archiv 2012, 460:271-279.
37. Xia S., Feng Z., Qi X., et al. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma. Medical Oncology 2015, 32:358.
38. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer 2002, 2:442-454.
39. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer and Metastasis Reviews 2009, 28:15-33.
40. Huang X.Y., Zhang C., Cai J.B., et al. Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients. PLOS ONE 2014, 9:e96860.
41. Zong Y., Panikkar A., Xu J., et al. Notch signaling controls liver development by regulating biliary differentiation. Development 2009, 136:1727-1739.
42. Dill M.T., Tornillo L., Fritzius T., et al. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 2013, 57:1607-1619.
43. El Khatib M., Bozko P., Palagani V., et al. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLOS ONE 2013, 8:e77433.
44. Zhou Q., Wang Y., Peng B., et al. The roles of Notch1 expression in the migration of intrahepatic cholangiocarcinoma. BMC Cancer 2013, 13:244.
45. Mazur P.K., Riener M.O., Jochum W., et al. Expression and clinicopathological significance of notch signaling and cell-fate genes in biliary tract cancer. American Journal of Gastroenterology 2012, 107:126-135.
46. Zhao R., Duncan S.A. Embryonic development of the liver. Hepatology 2005, 41:956-967.
47. Spence J.R., Lange A.W., Lin S.C., et al. Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. Developmental Cell 2009, 17:62-74.